Objective:To investigate the in vitro interference of cefotaxime at subinhibitory concentrations [sub-minimal inhibitory concentrations(MIC)] on biofilm formation by nontypeable Haemophilus influenzae(NTHi).Methods:Th...Objective:To investigate the in vitro interference of cefotaxime at subinhibitory concentrations [sub-minimal inhibitory concentrations(MIC)] on biofilm formation by nontypeable Haemophilus influenzae(NTHi).Methods:The interference of subinhibitory concentrations of cefotaxime on biofilm formation of the clinical strong-biofilm forming isolates of NTHi was evaluated by a microtiter plate biofilm formation assay.The effect of sub-MIC cefotaxime on bacterial cell-surface hydrophobicity was determined using a standard microbial adhesion to n-hexadecane test.Additionally,the effects on bacterial adherence to human fibronectin and expression of bacterial adhesins were also investigated.Results:Subinhibitory concentrations of cefotaxime,both at 0.1× and 0.5× MIC levels,efficiently reduced the NTHi biofilm formation,and this effect was independent of decreasing bacterial viability.Sub-MIC cefotaxime also decreased bacterial cell-surface hydrophobicity and reduced adherence to human fibronectin.Inhibition in the P2 and P6 gene expressions upon exposure to sub-MIC cefotaxime was also noted.Conclusions:Taken together,our results indicate that sub-MIC cefotaxime interferes with the formation of NTHi biofilm,and this effect is feasibly related to the interference with cell-surface hydrophobicity,fibronectin-binding activity as well as alteration of the P2 and P6 gene expression.The findings of the present study therefore provide a rationale for the use of subinhibitory concentrations of cefotaxime for treatment of NTHi-related diseases.展开更多
目的:构建不可分型流感嗜血杆菌(nontypeableHaemophilus influenzae,NTHi)外膜蛋白P6(outermembrane protein P6,P6)真核表达的重组质粒,并在HeLa细胞中表达,为核酸疫苗的开发奠定基础。方法:以NTHi基因组为模板,扩增编码P6蛋白的基因...目的:构建不可分型流感嗜血杆菌(nontypeableHaemophilus influenzae,NTHi)外膜蛋白P6(outermembrane protein P6,P6)真核表达的重组质粒,并在HeLa细胞中表达,为核酸疫苗的开发奠定基础。方法:以NTHi基因组为模板,扩增编码P6蛋白的基因片段,酶切、纯化P6基因与真核载体pcDNA3.1/HisA后进行连接,之后转化并筛选含有目的基因的重组质粒pcDNA3.1/HisA-P6;将重组子转染至HeLa细胞,荧光蛋白法检测其表达产物。结果:经质粒PCR、酶切、测序证实插入的基因片段为NTHi-P6蛋白编码基因;荧光显微镜下显示,该重组质粒能够在HeLa细胞中表达目的蛋白。结论:成功地构建了真核重组质粒pcD-NA3.1/HisA-P6,并在HeLa细胞中表达。展开更多
基金Supported by the National Research Council of Thailand through the Annual Research Fund of Naresuan University(Grant No.R2557B011)
文摘Objective:To investigate the in vitro interference of cefotaxime at subinhibitory concentrations [sub-minimal inhibitory concentrations(MIC)] on biofilm formation by nontypeable Haemophilus influenzae(NTHi).Methods:The interference of subinhibitory concentrations of cefotaxime on biofilm formation of the clinical strong-biofilm forming isolates of NTHi was evaluated by a microtiter plate biofilm formation assay.The effect of sub-MIC cefotaxime on bacterial cell-surface hydrophobicity was determined using a standard microbial adhesion to n-hexadecane test.Additionally,the effects on bacterial adherence to human fibronectin and expression of bacterial adhesins were also investigated.Results:Subinhibitory concentrations of cefotaxime,both at 0.1× and 0.5× MIC levels,efficiently reduced the NTHi biofilm formation,and this effect was independent of decreasing bacterial viability.Sub-MIC cefotaxime also decreased bacterial cell-surface hydrophobicity and reduced adherence to human fibronectin.Inhibition in the P2 and P6 gene expressions upon exposure to sub-MIC cefotaxime was also noted.Conclusions:Taken together,our results indicate that sub-MIC cefotaxime interferes with the formation of NTHi biofilm,and this effect is feasibly related to the interference with cell-surface hydrophobicity,fibronectin-binding activity as well as alteration of the P2 and P6 gene expression.The findings of the present study therefore provide a rationale for the use of subinhibitory concentrations of cefotaxime for treatment of NTHi-related diseases.
文摘目的:构建不可分型流感嗜血杆菌(nontypeableHaemophilus influenzae,NTHi)外膜蛋白P6(outermembrane protein P6,P6)真核表达的重组质粒,并在HeLa细胞中表达,为核酸疫苗的开发奠定基础。方法:以NTHi基因组为模板,扩增编码P6蛋白的基因片段,酶切、纯化P6基因与真核载体pcDNA3.1/HisA后进行连接,之后转化并筛选含有目的基因的重组质粒pcDNA3.1/HisA-P6;将重组子转染至HeLa细胞,荧光蛋白法检测其表达产物。结果:经质粒PCR、酶切、测序证实插入的基因片段为NTHi-P6蛋白编码基因;荧光显微镜下显示,该重组质粒能够在HeLa细胞中表达目的蛋白。结论:成功地构建了真核重组质粒pcD-NA3.1/HisA-P6,并在HeLa细胞中表达。
